Today's news is a milestone achievement that could see PTX...

Today's news is a milestone achievement that could see PTX become a pharmaceutical company. First cab off the rank Mycosis Fungoides and, if so, Sézary Syndrome (the rarer and more aggressive of the two most common CTCL indications) could feasibly be an off-label recipient. PTCL is still in an open and active Ph1b trial (recruitment pending results of the CTCL trial). So, bring on a future investigator-led PTCL trial, and PTX-100 would be well on its way to opening other doors. As James McD states, "we have an obligation to explore broader applications of this drug" (or words to that effect). Its been the FDA's mission to support therapies with broader applicability (especially those that provide less side effects and cause a burden on the health system). Patients also want safer alternatives... and PTX-100 fits that bill so far.